Fragment-Based Drug Discovery – July 19-22, 2014

Fragment-Based Drug Discovery, Punta Cana.  IntelliSyn will be presenting recent results in a presentation entitled: “Extending the range of fragment methodologies:  Applications in the absence of crystallography”. 

Mastering Medicinal Chemistry – May 21-23, 2014

Mastering Medicinal Chemistry, Boston, Massachusetts.  IntelliSyn will present on the following: “Development of highly potent, selective BET bromodomain inhibitors that are CNS penetrant and effective in rodent models of brain cancer.”

IntelliSyn Achieves Milestone and Partners Cancer Project

April 1, 2014 – IntelliSyn successfully reaches its milestone with Epigenetix and partners its BRD4 inhibitor project with the NeoMed Institute to advance to clinical trials.

IntelliSyn expands to new facilities at the NeoMed Institute

July 1, 2013 – IntelliSyn expands to new facilities at the NeoMed Institute the Montreal Technopark.  It is a first-tier R&D facility that has been specifically designed for early R&D work. The building is state-of-the-art  and fully equipped for chemistry, biology or drug metabolism studies.